Concerns about whether Coke Zero causes fatty liver disease reflect growing public interest in the health effects of artificially sweetened drinks. Fatty liver disease, or non-alcoholic fatty liver disease (NAFLD), affects approximately one in three UK adults and is closely linked to obesity, type 2 diabetes, and metabolic syndrome. Whilst Coke Zero contains no sugar or calories, questions remain about how artificial sweeteners might indirectly influence metabolic and liver health. Current evidence does not show that Coke Zero directly causes fatty liver, but understanding the nuances of diet drinks, liver function, and overall metabolic health is essential for making informed choices.

What Is Fatty Liver Disease and What Causes It?

Fatty liver disease, medically termed hepatic steatosis, occurs when excess fat accumulates in liver cells. The condition is broadly classified into two main types: alcohol-related fatty liver disease (ARLD) and non-alcoholic fatty liver disease (NAFLD). NAFLD is increasingly common in the UK, affecting approximately one in three adults to some degree, and represents a significant public health concern.

NAFLD is defined as more than 5% of liver cells (hepatocytes) containing fat, despite minimal or no alcohol consumption. The condition exists on a spectrum, ranging from simple steatosis (fat accumulation without inflammation) to non-alcoholic steatohepatitis (NASH), which involves inflammation and liver cell damage. In some cases, NASH can progress to cirrhosis, liver failure, or hepatocellular carcinoma (liver cancer) if left unmanaged. It is important to note that liver blood tests (liver enzymes such as ALT and AST) may be normal even when NAFLD or NASH is present, so normal results do not exclude the condition.

The primary risk factors for NAFLD include:

• Obesity and excess body weight, particularly central adiposity (fat around the abdomen)

• Type 2 diabetes mellitus and insulin resistance

• Metabolic syndrome (a cluster of conditions including high blood pressure, elevated blood glucose, and abnormal cholesterol levels)

• High triglyceride levels and dyslipidaemia

• Sedentary lifestyle and poor dietary habits

The underlying mechanism involves insulin resistance, which disrupts normal fat metabolism. When cells become less responsive to insulin, the liver increases fat production whilst simultaneously reducing fat breakdown. This metabolic dysfunction leads to progressive fat accumulation. Additional factors such as genetic predisposition, certain medications, and rapid weight loss can also contribute to fatty liver development.

Medications and other causes that may contribute to fatty liver include:

• Corticosteroids

• Some chemotherapy agents

• Amiodarone (heart rhythm medication)

• Valproate (epilepsy medication)

• Methotrexate (used for arthritis and other conditions)

• Tamoxifen (breast cancer treatment)

• Some antiretroviral medicines (for HIV)

• Total parenteral nutrition (intravenous feeding)

If you take any of these medicines, do not stop them without speaking to your GP or specialist. A medication review may be appropriate if you have concerns about liver health.

Most people with early-stage NAFLD experience no symptoms. The condition is often detected incidentally through blood tests showing elevated liver enzymes or during imaging studies performed for other reasons. As the disease progresses, individuals may develop fatigue, discomfort in the upper right abdomen, or signs of advanced liver disease. You may also hear the term MASLD (metabolic dysfunction-associated steatotic liver disease) in current literature; this is a newer term that is essentially equivalent to NAFLD in UK practice.

Does Coke Zero Cause Fatty Liver?

There is no conclusive evidence that Coke Zero directly causes fatty liver disease in humans. However, this question reflects growing public concern about the potential health effects of artificially sweetened beverages, particularly regarding metabolic and liver health. Understanding the nuances of current evidence is essential for making informed dietary choices.

Coke Zero and similar diet drinks contain artificial sweeteners—primarily aspartame and acesulfame potassium—instead of sugar. Unlike regular cola, which contains approximately 35g of sugar per 330ml can, Coke Zero provides sweetness without the caloric load or glucose spike associated with sugar-sweetened beverages. From a purely caloric perspective, this substitution can be beneficial, as excess sugar consumption is a well-established risk factor for NAFLD. Replacing sugar-sweetened drinks with low- or no-sugar alternatives can help reduce overall energy intake and may support weight management, which in turn benefits liver health.

The UK Food Standards Agency (FSA) and the European Food Safety Authority (EFSA), along with the Joint FAO/WHO Expert Committee on Food Additives (JECFA), have approved the artificial sweeteners used in Coke Zero as safe for human consumption within acceptable daily intake (ADI) limits. For example, the EFSA ADI for aspartame is 40 mg per kilogram of body weight per day, and for acesulfame potassium it is 9 mg/kg/day. Typical consumption levels are well below these limits. These regulatory bodies have not identified direct liver toxicity from these sweeteners at normal consumption levels.

However, the relationship between diet drinks and metabolic health is more complex than simple calorie counting suggests. Emerging research indicates potential indirect mechanisms through which artificial sweeteners might influence metabolic health, including alterations to gut microbiota, insulin signalling, and appetite regulation. These effects remain subjects of ongoing investigation and scientific debate, and most are based on animal studies or observational data in humans rather than definitive clinical trials.

It is important to distinguish between direct causation and association. Whilst some observational studies have noted correlations between diet drink consumption and metabolic conditions, these associations do not prove causation. Confounding factors—such as overall dietary patterns, lifestyle behaviours, and pre-existing health conditions—make it difficult to isolate the specific effects of artificial sweeteners. People who consume diet drinks may already have metabolic concerns or unhealthy dietary habits that independently increase fatty liver risk (a phenomenon known as reverse causation).

Artificial Sweeteners and Liver Health: What the Evidence Shows

The scientific literature examining artificial sweeteners and liver health presents a mixed and evolving picture. Current evidence does not demonstrate that artificial sweeteners directly damage the liver or cause fatty liver disease in humans when consumed within acceptable daily intake limits, but several research areas warrant attention and continued investigation.

Animal studies have produced variable results. Some rodent research has suggested that certain artificial sweeteners may influence glucose metabolism and insulin sensitivity, potentially creating metabolic conditions that favour fat accumulation. However, translating these findings to humans requires caution, as rodents metabolise these compounds differently and are often exposed to doses far exceeding typical human consumption levels.

Human observational studies have shown associations between diet drink consumption and metabolic syndrome components, including increased waist circumference and elevated fasting glucose. Large prospective cohort studies have noted that regular diet drink consumers had higher rates of metabolic syndrome over time compared to non-consumers. However, these observational studies cannot establish causation—it remains unclear whether the beverages themselves contribute to metabolic dysfunction or whether people with existing metabolic concerns are more likely to choose diet drinks. Confounding by overall diet quality, physical activity, and other lifestyle factors is difficult to fully account for in such studies.

Randomised controlled trials (RCTs), which provide stronger evidence, have generally shown neutral effects on blood glucose and insulin when energy intake is matched between groups. Systematic reviews and meta-analyses of RCTs suggest that when artificial sweeteners replace sugar in an otherwise controlled diet, metabolic outcomes are largely neutral or modestly beneficial due to reduced energy intake.

Mechanistic research has identified several potential pathways, though these remain largely theoretical in humans:

• Gut microbiome alterations: Some studies suggest artificial sweeteners may modify intestinal bacteria composition, potentially affecting metabolic signalling and inflammation. However, the clinical significance of these changes in humans is not yet established.

• Insulin response dysregulation: It has been hypothesised that sweet taste perception may trigger cephalic phase insulin responses, potentially affecting glucose homeostasis over time. Human evidence for this mechanism is inconsistent and requires further study.

• Appetite and reward pathway effects: Artificial sweeteners may influence brain reward centres and appetite regulation, potentially leading to compensatory eating behaviours in some individuals.

The European Food Safety Authority and JECFA continue to monitor safety data on approved sweeteners. Recent comprehensive reviews have reaffirmed that consumption within acceptable daily intake levels does not pose direct health risks, though they acknowledge that long-term metabolic effects require further study. The World Health Organization published guidance in 2023 on non-sugar sweeteners, noting that whilst they do not directly cause harm, they should not be relied upon as a primary strategy for weight control. NICE guidance on NAFLD (NG49) does not specifically identify artificial sweeteners as risk factors but emphasises overall dietary quality and metabolic health.

How Diet Drinks May Affect Metabolism and Liver Function

Understanding how diet drinks might indirectly influence liver health requires examining broader metabolic effects. Whilst artificial sweeteners do not provide calories or directly increase liver fat synthesis, they may affect metabolic processes that ultimately influence liver health through several interconnected mechanisms.

Insulin sensitivity and glucose metabolism represent key areas of investigation. Some observational research suggests that regular consumption of artificially sweetened beverages may be associated with altered insulin responses and glucose handling. The proposed mechanism involves the dissociation between sweet taste perception and caloric delivery, which may disrupt normal metabolic signalling pathways. However, most short-term randomised controlled trials in humans show neutral glycaemic effects when energy intake is matched, and the clinical significance of any effects remains uncertain and likely varies between individuals.

The gut-liver axis has emerged as an important consideration. The liver receives approximately 70% of its blood supply from the intestinal circulation via the portal vein, creating a direct connection between gut health and liver function. Artificial sweeteners may alter gut microbiota composition in some individuals, potentially increasing intestinal permeability and inflammatory signalling. These changes could theoretically influence liver inflammation and fat metabolism, though definitive evidence in humans is lacking and these mechanisms remain hypothesis-generating.

Behavioural and dietary compensation may represent the most significant indirect pathway. Some individuals consuming diet drinks may unconsciously compensate by eating more calories elsewhere, potentially negating any caloric benefit. Additionally, diet drink consumption often occurs within broader dietary patterns characterised by processed foods and inadequate whole food intake—patterns independently associated with metabolic dysfunction and fatty liver risk. Conversely, evidence from trials shows that replacing sugar-sweetened beverages with diet drinks can support weight control and reduce energy intake, which benefits NAFLD risk.

It is crucial to emphasise that individual responses vary considerably. Factors including genetic predisposition, existing metabolic health, overall dietary quality, physical activity levels, and gut microbiome composition all influence how diet drinks affect metabolism. For most people consuming moderate amounts within acceptable daily intake limits as part of an otherwise healthy lifestyle, significant metabolic disruption is unlikely. However, those with pre-existing insulin resistance, obesity, or metabolic syndrome may wish to prioritise water and other unsweetened beverages.

Protecting Your Liver: Practical Steps and Healthier Alternatives

Protecting liver health requires a comprehensive approach focused on evidence-based lifestyle modifications rather than fixating on single dietary components. NICE guidance on NAFLD (NG49) emphasises weight management, dietary quality, and physical activity as cornerstones of prevention and treatment.

Practical steps to support liver health include:

• Achieve and maintain a healthy weight: Even modest weight loss (5–10% of body weight) can significantly reduce liver fat content and improve liver enzyme levels in people with NAFLD

• Follow a balanced, whole-food diet: Emphasise vegetables, fruits, whole grains, lean proteins, and healthy fats whilst limiting processed foods, refined carbohydrates, and added sugars

• Engage in regular physical activity: Aim for at least 150 minutes of moderate-intensity exercise weekly, as recommended by NHS guidelines. Both aerobic exercise and resistance training benefit liver health

• Limit alcohol consumption: Follow UK Chief Medical Officers' guidelines of no more than 14 units weekly, spread over three or more days, with several alcohol-free days each week

• Manage underlying conditions: Optimise control of diabetes, hypertension, and dyslipidaemia (abnormal cholesterol) through medication adherence and lifestyle measures

• Review your medications: If you take medicines that may affect the liver (such as amiodarone, valproate, methotrexate, or others listed earlier), discuss this with your GP. Do not stop any prescribed medicine without medical advice.

Regarding beverage choices, water remains the optimal hydration source. For those seeking alternatives to sugar-sweetened drinks, consider:

• Plain or sparkling water with fresh lemon, lime, or cucumber

• Herbal teas (hot or iced) without added sweeteners

• Small amounts of unsweetened fruit juice diluted with water

• Milk or plant-based alternatives (unsweetened varieties)

If you choose to consume diet drinks, moderation is advisable. Occasional consumption as part of an otherwise healthy dietary pattern is unlikely to cause harm for most individuals, and replacing sugar-sweetened beverages with diet versions can reduce energy intake. However, water and other unsweetened drinks should be your first choice. Staying within acceptable daily intake limits for sweeteners (for example, aspartame 40 mg/kg/day; acesulfame K 9 mg/kg/day) provides a wide safety margin; typical consumption is well below these levels.

NHS assessment pathway for NAFLD: If you have risk factors for fatty liver disease—including obesity, type 2 diabetes, or metabolic syndrome—your GP may assess your risk using a blood test-based score called FIB-4. Low-risk thresholds are FIB-4 <1.3 if you are under 65 years, or <2.0 if you are 65 or older. If your FIB-4 score is indeterminate or high, your GP may arrange an Enhanced Liver Fibrosis (ELF) blood test. A result of 10.51 or above, or other concerning features, may prompt referral to a liver specialist (hepatologist). It is important to know that normal liver enzyme blood tests do not exclude NAFLD or NASH.

Imaging tests such as ultrasound or FibroScan may be used to assess the liver, though ultrasound can miss mild fat accumulation and FibroScan availability varies across the NHS.

When to seek medical advice: Contact your GP if you experience persistent fatigue, unexplained weight loss, abdominal discomfort, or if you have risk factors for fatty liver and have not been assessed. Seek urgent same-day medical help (contact your GP, call NHS 111, or attend A&E) if you develop:

• Jaundice (yellowing of the skin or whites of the eyes), especially with fever or confusion

• Vomiting blood or passing black, tarry stools

• Severe abdominal pain with fever

• Rapidly progressive abdominal swelling

• Confusion or drowsiness that is unusual for you

Early detection and intervention significantly improve outcomes, potentially preventing progression to advanced liver disease.

Reporting side effects: If you suspect that a medicine or vaccine has caused a side effect, you can report it via the MHRA Yellow Card Scheme at https://yellowcard.mhra.gov.uk or by searching for 'Yellow Card' in the Google Play or Apple App Store.

Frequently Asked Questions